MYC regulates the antitumor immune response through CD47 and PD-L1
Author(s) -
Stephanie C. Casey,
Ling Tong,
Yulin Li,
Rachel Do,
Susanne Walz,
Kelly N. Fitzgerald,
Arvin M. Gouw,
Virginie Baylot,
Ines Gütgemann,
Martin Eilers,
Dean W. Felsher
Publication year - 2016
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aac9935
Subject(s) - immune system , biology , oncogene , cd47 , immune checkpoint , cancer research , transcription factor , carcinogenesis , regulator , pd l1 , proto oncogene proteins c myc , acquired immune system , immune tolerance , microbiology and biotechnology , immunotherapy , immunology , gene , cell cycle , genetics
The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in the levels of CD47 and PD-L1 messenger RNA and protein. MYC was found to bind directly to the promoters of the Cd47 and Pd-l1 genes. MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the antitumor immune response. In contrast, when MYC was inactivated in tumors with enforced expression of CD47 or PD-L1, the immune response was suppressed, and tumors continued to grow. Thus, MYC appears to initiate and maintain tumorigenesis, in part, through the modulation of immune regulatory molecules.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom